Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
SUMMARIES FOR PATIENTS
The Cost-Effectiveness of Aspirin, Statins, or Both Drugs in the Primary Prevention of Heart Disease
7 March 2006 | Volume 144 Issue 5 | Page I-29
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians.
The summary below is from the full report titled "Aspirin, Statins, or Both Drugs for the Primary Prevention of Coronary Heart Disease Events in Men: A CostUtility Analysis." It is in the 7 March 2006 issue of Annals of Internal Medicine (volume 144, pages 326-336). The authors are M. Pignone, S. Earnshaw, J.A. Tice, and M.J. Pletcher.
What is the problem and what is known about it so far?
![]()
Heart attack occurs when blockage develops in the blood vessels that supply the heart muscle. Heart attacks are one of the most common causes of illness and are the leading cause of death in the United States. Certain conditions ("risk factors") increase a person's chance of having a heart attack or other cardiovascular event. They include older age, male sex, high blood pressure, diabetes, smoking, high levels of total or low-density lipoprotein ("bad") cholesterol or low levels of high-density lipoprotein ("good") cholesterol in the blood, and close relatives who had heart attacks before 60 years of age. Aspirin decreases the chances of a heart attack in people who have had previous heart attacks (secondary prevention) and in people who have risk factors but have not yet had a heart attack (primary prevention). Statins are medications that treat high blood cholesterol levels. Many studies show that statins are effective in the primary and secondary prevention of heart attacks and other cardiovascular events. Although aspirin and statins are each known to be effective in the primary prevention of heart attacks and other cardiovascular events, the cost-effectiveness of using 1 drug, the other, or both drugs together is not known.
Why did the researchers do this particular study?
![]()
To compare the costs and benefits of using aspirin, statins, both drugs, or neither drug for the primary prevention of heart attacks and other cardiovascular events in men.
Who was studied?
![]()
Instead of studying actual patients, the researchers used computers to simulate what would happen to a group of middle-aged men with no history of heart disease who had various risk factors for experiencing a heart attack in the future.
How was the study done?
![]()
The researchers used published information to estimate what might happen (and how much it would cost) if doctors prescribed aspirin, statins, both drugs, or neither drug for middle-aged men. They put these estimates into the computer model and calculated how much longer the men would live with each treatment and how much treatment would cost for each of those additional years.
What did the researchers find?
![]()
Compared with no treatment, aspirin therapy saved years of life and costs for middle-aged men whose chance of having a heart attack or related cardiovascular event within the next 10 years was 7.5% (7.5 in 100). The addition of a statin to aspirin therapy became cost-effective if the patient's risk was 10% (10 out of 100) or greater.
What were the limitations of the study?
![]()
This study was a computer simulation. We cannot be sure what the results would be with actual patients. These estimates can be useful, however, because studies of this problem involving actual patients are unlikely to be done soon, if ever. The findings may not apply to women.
What are the implications of the study?
![]()
Middle-aged men whose chance of having a heart attack or related cardiovascular event within the next 10 years is 7.5% should consider taking aspirin for primary prevention. Men whose risk is greater than 10% should consider taking both aspirin and a statin. A tool to calculate risk of heart attack is available at http://www.med-decisions.com.
Related articles in Annals:
This article has been cited by other articles:
![]() |
J. P. Greving, E. Buskens, H. Koffijberg, and A. Algra Cost-Effectiveness of Aspirin Treatment in the Primary Prevention of Cardiovascular Disease Events in Subgroups Based on Age, Gender, and Varying Cardiovascular Risk Circulation, June 3, 2008; 117(22): 2875 - 2883. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Morgan Affordability calculations on a health education campaign to promote the use of aspirin in Wales Health Education Journal, March 1, 2008; 67(1): 31 - 34. [Abstract] [PDF] |
||||
![]() |
K. Dalziel and L. Segal Time to give nutrition interventions a higher profile: cost-effectiveness of 10 nutrition interventions Health Promot. Int., December 1, 2007; 22(4): 271 - 283. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Mantha, J. Foss, J. E. Ellis, and M. F. Roizen Intense Cardiac Troponin Surveillance for Long-Term Benefits Is Cost-Effective in Patients Undergoing Open Abdominal Aortic Surgery: A Decision Analysis Model Anesth. Analg., November 1, 2007; 105(5): 1346 - 1356. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Fidan, B. Unal, J. Critchley, and S. Capewell Economic analysis of treatments reducing coronary heart disease mortality in England and Wales, 2000-2010 QJM, May 1, 2007; 100(5): 277 - 289. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Martinez and E. R. Greenberg More Aspirin for Less Cancer? J Natl Cancer Inst, April 18, 2007; 99(8): 582 - 583. [Full Text] [PDF] |
||||
![]() |
P. Thavendiranathan, A. Bagai, M. A. Brookhart, and N. K. Choudhry Primary Prevention of Cardiovascular Diseases With Statin Therapy: A Meta-analysis of Randomized Controlled Trials Arch Intern Med, November 27, 2006; 166(21): 2307 - 2313. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. K. Chelmowski Cost-effectiveness of statins added to aspirin therapy. Ann Intern Med, August 1, 2006; 145(3): 233 - 233. [Full Text] [PDF] |
||||
![]() |
I. Malik JournalScan Heart, June 1, 2006; 92(6): 862 - 864. [Full Text] [PDF] |
||||
![]() |
Cost-Effectiveness of Primary-Prevention Therapy with Aspirin plus Statins Journal Watch Cardiology, April 6, 2006; 2006(406): 5 - 5. [Full Text] |
||||
Read all Rapid Responses
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||